Skyhawk Applies for Provisional Australian Approval of SKY-0515 RNA-Splicing HD Therapy The Australian TGA determined SKY-0515, an oral RNA-splicing therapy for HD, is eligible to apply for provisional approval.

Skyhawk Therapeutics announced that SKY-0515, an investigational oral RNA-splicing therapy for #HuntingtonDisease (HD), has met the eligibility criteria to apply for provisional approval by the Australian Therapeutic Goods Administration.

Read more: https://bit.ly/4cpZeZ6

#RareDisease #SKY0515

Positive 9-Month Findings From Phase 1 Trial of SKY-0515 for Huntington Disease Patients with HD who received SKY-0515 showed a mean 0.64-point improvement on the cUHDRS, compared with the expected 0.73-point decline.

Skyhawk Therapeutics announced positive 9-month interim findings from its phase 1 clinical trial of SKY-0515 for the treatment of #HuntingtonDisease (HD).

Read more: https://bit.ly/4tbDFl3

#RareDisease #SKY0515 #SkyhawkTherapeutics